Vertex Pharmaceuticals (VRTX) Enterprise Value (2009 - 2026)

Vertex Pharmaceuticals' Enterprise Value history runs 18 years deep, the most recent figure standing at -$7.2 billion for Q1 2026.

• In Q1 2026, Enterprise Value fell 16.86% year-over-year to -$7.2 billion; the TTM figure through Mar 2026 stood at -$7.2 billion (down 16.86% YoY), while the FY2025 annual figure was -$6.6 billion, down 8.05% from the prior year.
• Enterprise Value was -$7.2 billion for Q1 2026 at Vertex Pharmaceuticals, down from -$6.6 billion in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$5.8 billion in Q2 2024 to a low of -$11.9 billion in Q3 2023.
• Historically, Enterprise Value has averaged -$8.5 billion across 5 years, with a median of -$8.2 billion in 2022.
• The sharpest annual moves came in 2022 and 2024: Enterprise Value plunged 43.24% in 2022, then surged 48.42% in 2024.
• A 5-year view of Enterprise Value shows it stood at -$10.8 billion in 2022, then fell by 4.08% to -$11.2 billion in 2023, then soared by 45.48% to -$6.1 billion in 2024, then retreated by 8.05% to -$6.6 billion in 2025, then dropped by 9.66% to -$7.2 billion in 2026.
• The last three Enterprise Value figures came in at -$7.2 billion (Q1 2026), -$6.6 billion (Q4 2025), and -$6.3 billion (Q3 2025), per Business Quant data.